A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2

Primary Objectives:Cohort A:• To evaluate the efficacy of REGN10933+REGN10987 compared to placebo in preventing symptomatic SARS-CoV-2 infection (broad-term) confirmed by RT-qPCRCohort A and Cohort A1:• To evaluate the safety and tolerability of REGN10933+REGN10987 following subcutaneous (SC) administration compared to placeboCohort B • To evaluate the efficacy of REGN10933+REGN10987 compared to placebo in preventing COVID-19 symptoms (broad-term)Cohort B and Cohort B1• To evaluate the safety and tolerability of REGN10933+REGN10987 following SC administration compared to placebo